Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies

Value in Health

Volumn 3, Issue 3, 2000, Pages 232-242

  Tunis, Sandra L ^a,b   Johnstone, Bryan M ^a,c   Kinon, Bruce J ^a   Barber, Beth L ^a   Browne, Robert A ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Cost effectiveness; Economic clinical trial; Medical effectiveness study; Olanzapine; Pharmacoeconomics; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ARTICLE; DRUG CHOICE; DRUG COST; HUMAN; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA;

EID: 0033877139     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.33007.x     Document Type: Article

References (56)

1. Drummond MF, Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assess Health Care 1991;7(4):561-73.
2. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using real world randomized trials: The case of new antidepressant drugs. J Clin Epidemiol 1995;48(3):363-73.
3. Powe NR, Griffiths RI. The Clinical-Economic Trial. Promise, problems, and challenges. Control Clin Trials 1995;16:377-94.
4. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Diseases 1967;20(8):637-48.
5. Drummond MF, Richardson WS, O'Brien BJ, et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1997;277(19):1552-7.
6. Revicki DA. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999;15(5):423-34.
7. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31(1): 57-65.
8. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57(Suppl 9):66-76.
9. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 1996;32(4):683-97.
10. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New Engl J Med 1997;337(12):809-15.
11. Cook TD, Campell DT. Quasi-Experimentation: design and analysis issues for field settings. Boston: Houghton Mifflin Co., 1979.
12. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997;58(Suppl 10):50-54.
13. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
14. Siegel JE, Torrance GW, Russell LB. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-68.
15. Rajagopalan R, Kallal JE, Fowler JF Jr, et al. Practical issues in conducting pharmacoeconomic studies. Clin Ther 1996;18(6):1298-1306.
16. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, strategies. Clin Ther 1997;19(2):346-66.
17. Rice DP, Miller LS. The economic burden of schizophrenia. Conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N (eds.). Handbook of Mental Health Economics and Health Policy. New York: John Wiley and Sons, 1996.
18. Carpenter WT Jr, Buchanan RW. Schizophrenia. New Engl J Med 1994;330(10):681-90.
19. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21(3):419-29.
20. Loebel AD, Botts SR, Feldman BI. Atypical antipsychotics in the managed care era. Am J Manag Care 1998;4:50.
21. Cohen LJ. Antipsychotic medications. Present and future. Am J Managed Care 1998;4(Suppl):S31-5.
22. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154(4):466-74.
23. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55(3):250-8.
24. Tunis SL, Croghan TW, Heilman DK, et al. Reliability, validity, and application of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999; 37(7):678-91.
25. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999;8(5):417-26.
26. Meyer P, Bond G, McCoy M, et al. The influence of atypical antipsychotics on work outcomes. Paper presented at the International Congress on Schizophrenia Research. Santa Fe, NM, April 17-21, 1999.
27. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Implications for the post-institutional era in the Unites States. Pharmacoeconomics 1995;8(3):199-222.
28. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989;262(20):2879-86.
29. Buckley PR. Treatment of schizophrenia: let's talk dollars and sense. Am J Manag Care 1998;4:369-83.
30. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17(5):407-18.
31. Bever KA, Perry PJ. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Health-System Pharmacy 1998; 55(10): 1003-16.
32. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154(4):457-65.
33. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14(2): 111-23.
34. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124(1-2):159-67.
35. Obenchain RL, Johnstone BM. Mixed model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Inf J 1999; 33:191-209.
36. Hamilton SH, Revicki DA, Edgell ET, et al. Costs and economic outcomes of treatment compared with haloperidol for schizophrenia. Results from a randomized clinical trial. Pharmacoeconomics 1999; 15(5):469-80.
37. Freemantle N, Drummond M. Should clinical trials with concurrent economic analyses be blinded? JAMA 1997;277(1):63-4.
38. American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Assocation, 1994.
39. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(4 Suppl):1-63.
40. Iezzoni LI. Risk adjustment for medical effectiveness research: an overview of conceptual and methodological considerations. J Investig Med 1995;43(2):136-50.
41. Shwartz M, Iezzoni LI, Moskowitz MA, et al. The importance of comorbidities in explaining differences in patient costs. Med Care 1996;34(8): 767-82.
42. Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998;59(Suppl 3):26-30.
43. Bartels SJ, Teague GB, Drake RE, et al. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis 1993;181(4):227-32.
44. Bradley CJ, Zarkin GA. Inpatient stays for patients diagnosed with severe psychiatric disorders and substance abuse. Health Serv Res 1996;31(4): 387-408.
45. Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999;60(Suppl 19):S47-51.
46. Mahmoud R, Engelhart L, Ollendorf D, et al. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 1999;60(Suppl 3):S42-8.
47. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. New Engl J Med 1987; 317(7):426-32.
48. Tunis SL, Johnstone BM, Gibson PJ, et al. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999; 60(Suppl 19):S38-45.
49. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
50. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 24(1):97-9.
51. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) manual. North Tonawanda, NY: Multi-Health Systems, 1986.
52. Andreason N. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995;346:477-81.
53. Lehman AF, Burns BJ. Severe mental illness in the community. In: Spilker B (ed.). Quality of Life Assessments in Clinical Trials. New York: Raven Press, 1990.
54. Rittenhouse BE, Dulisse B, Stinnett AA. At what price significance? The effect of price estimates on statistical inference in economic evaluation. Health Econ 1999;8(3):213-9.
55. Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996;57(Suppl):S61-7.
56. McCombs JS, Nichol MB, Stimmel GL, et al. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 1999;60(Suppl 19):S5-13.